Berenberg analyst Zhiqiang Shu initiated coverage of Ideaya Biosciences with a Buy rating and $26 price target, implying 85% upside. Ideaya is a clinical-stage biotech company that develops cancer drugs using its synthetic lethality platform, the analyst tells investors in a research note. The firm views Ideaya as an attractive opportunity, saying a potential near-term value driver is the success of PKC inhibitor darovasertib in metastatic uveal melanoma studies.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IDYA:
- Ideaya Biosciences price target raised to $29 from $26 at Citi
- Ideaya Buy thesis ‘remains intact’ after Q4 report, says Capital One
- Ideaya Biosciences reports Q4 EPS (50c), consensus (56c)
- IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update
- Ideaya Biosciences initiated with an Outperform at RBC Capital
